184 related articles for article (PubMed ID: 38612621)
21. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy.
Kessler T; Latzer P; Schmid D; Warnken U; Saffari A; Ziegler A; Kollmer J; Möhlenbruch M; Ulfert C; Herweh C; Wildemann B; Wick W; Weiler M
J Neurochem; 2020 Jun; 153(5):650-661. PubMed ID: 31903607
[TBL] [Abstract][Full Text] [Related]
22. Quality of life assessment in adult spinal muscular atrophy patients treated with nusinersen.
Bonanno S; Zanin R; Bello L; Tramacere I; Bozzoni V; Caumo L; Ferraro M; Bortolani S; Sorarù G; Silvestrini M; Vacchiano V; Turri M; Tanel R; Liguori R; Coccia M; Mantegazza RE; Mongini T; Pegoraro E; Maggi L
J Neurol; 2022 Jun; 269(6):3264-3275. PubMed ID: 34978620
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
[TBL] [Abstract][Full Text] [Related]
24. Nusinersen for Spinal Muscular Atrophy in the United States: Findings From a Retrospective Claims Database Analysis.
Gauthier-Loiselle M; Cloutier M; Toro W; Patel A; Shi S; Davidson M; Bischof M; LaMarca N; Dabbous O
Adv Ther; 2021 Dec; 38(12):5809-5828. PubMed ID: 34713391
[TBL] [Abstract][Full Text] [Related]
25. Inflammatory markers in cerebrospinal fluid of paediatric spinal muscular atrophy patients receiving nusinersen treatment.
Scheijmans FEV; Cuppen I; Zwartkruis MM; Signoria I; van Ekris C; Asselman F; Wadman RI; Knol EF; van der Pol WL; Groen EJN
Eur J Paediatr Neurol; 2023 Jan; 42():34-41. PubMed ID: 36525882
[TBL] [Abstract][Full Text] [Related]
26. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
27. Assessment of cerebral spinal fluid biomarkers and microRNA-mediated disease mechanisms in spinal muscular atrophy patient samples.
Welby E; Rehborg RJ; Harmelink M; Ebert AD
Hum Mol Genet; 2022 Jun; 31(11):1830-1843. PubMed ID: 34919695
[TBL] [Abstract][Full Text] [Related]
28. Increased chitotriosidase 1 concentration following nusinersen treatment in spinal muscular atrophy.
Freigang M; Steinacker P; Wurster CD; Schreiber-Katz O; Osmanovic A; Petri S; Koch JC; Rostásy K; Falkenburger B; Ludolph AC; Otto M; Hermann A; Günther R
Orphanet J Rare Dis; 2021 Jul; 16(1):330. PubMed ID: 34321067
[TBL] [Abstract][Full Text] [Related]
29. Nusinersen treatment significantly improves hand grip strength, hand motor function and MRC sum scores in adult patients with spinal muscular atrophy types 3 and 4.
De Wel B; Goosens V; Sobota A; Van Camp E; Geukens E; Van Kerschaver G; Jagut M; Claes K; Claeys KG
J Neurol; 2021 Mar; 268(3):923-935. PubMed ID: 32935160
[TBL] [Abstract][Full Text] [Related]
30. Drug treatment for spinal muscular atrophy type I.
Wadman RI; van der Pol WL; Bosboom WM; Asselman FL; van den Berg LH; Iannaccone ST; Vrancken AF
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD006281. PubMed ID: 31825542
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
32. Cognitive performance of adult patients with SMA before and after treatment initiation with nusinersen.
Vidovic M; Freigang M; Aust E; Linse K; Petzold D; Günther R
BMC Neurol; 2023 Jun; 23(1):216. PubMed ID: 37280513
[TBL] [Abstract][Full Text] [Related]
33. Response of plasma microRNAs to nusinersen treatment in patients with SMA.
Zaharieva IT; Scoto M; Aragon-Gawinska K; Ridout D; Doreste B; Servais L; Muntoni F; Zhou H
Ann Clin Transl Neurol; 2022 Jul; 9(7):1011-1026. PubMed ID: 35584175
[TBL] [Abstract][Full Text] [Related]
34. Real-World Data from Nusinersen Treatment for Patients with Later-Onset Spinal Muscular Atrophy: A Single Center Experience.
Mendonça RH; Polido GJ; Matsui C; Silva AMS; Solla DJF; Reed UC; Zanoteli E
J Neuromuscul Dis; 2021; 8(1):101-108. PubMed ID: 33074187
[TBL] [Abstract][Full Text] [Related]
35. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
36. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
37. Alteration of LARGE1 abundance in patients and a mouse model of 5q-associated spinal muscular atrophy.
Roos A; Schmitt LI; Hansmann C; Hezel S; Salmanian S; Hentschel A; Meyer N; Marina AD; Kölbel H; Kleinschnitz C; Schara-Schmidt U; Leo M; Hagenacker T
Acta Neuropathol; 2024 Mar; 147(1):53. PubMed ID: 38470509
[TBL] [Abstract][Full Text] [Related]
38. The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy.
Hepkaya E; Kılınç Sakallı AA; Ülkersoy İ; Başkan AK; Arslan H; Meral Ö; Dilek TD; Güler S; Saltık S; Çokuğraş H
Pediatr Int; 2022 Jan; 64(1):e15310. PubMed ID: 36310036
[TBL] [Abstract][Full Text] [Related]
39. Effect of nusinersen treatment on quality of life and motor function in adult patients with spinal muscular atrophy.
Şimşek Erdem N; Güneş Gencer GY; Alaamel A; Uysal H
Neuromuscul Disord; 2024 Mar; 36():28-32. PubMed ID: 38310720
[TBL] [Abstract][Full Text] [Related]
40. NFL is a marker of treatment response in children with SMA treated with nusinersen.
Olsson B; Alberg L; Cullen NC; Michael E; Wahlgren L; Kroksmark AK; Rostasy K; Blennow K; Zetterberg H; Tulinius M
J Neurol; 2019 Sep; 266(9):2129-2136. PubMed ID: 31123861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
